secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001493152-24-038933
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MangoRx launches oral Semaglutide weight-loss treatment 'Slim' at $299/month
----------------------------------------------------------------------------

- Launched oral Semaglutide ODT compounded with Vitamin B6, branded 'Slim', on MangoRx.com.
- Priced at $299 per month; available via MangoRx telemedicine platform with physician review.
- Targets global GLP-1 market projected to grow from $49.3B in 2024 to $157.5B by 2035 (Roots Analysis).
- CEO Jacob Cohen cites growing GLP-1 demand; product aims to boost revenue and market share.
- Oral dissolvable tablet format offers needle-free alternative to traditional injections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224038933/0001493152-24-038933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224038933/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-038933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer